Xeris Biopharma Holdings Inc (XERS) financials
Xeris Biopharma revenue and earnings by year
Xeris Biopharma's revenue was $292 million in the fiscal year to December 31, 2025, up 43.7% from the year before. Net income was $554,000, 0.2% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 86.4% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 292 | 203 | 164 | 110 | 50 | 20 | 3 | 2 | 2 | 1 |
| Revenue growth | 43.7% | 23.9% | 48.7% | 122.3% | 142.7% | 650.7% | 12.3% | 55.7% | 44.7% | — |
| Gross profit | 249 | 166 | 135 | 88 | 36 | 11 | 1 | — | 2 | 1 |
| Gross margin | 85.4% | 81.9% | 82.5% | 79.5% | 73.1% | 54.4% | 41.1% | — | 99.7% | 99.3% |
| Operating income | 25 | -34 | -44 | -82 | -115 | -84 | -122 | -59 | -27 | -13 |
| Operating margin | 8.5% | -16.6% | -26.8% | -74.3% | -232.2% | -408.8% | -4496.0% | -2449.2% | -1711.4% | -1230.8% |
| Net income | 1 | -55 | -62 | -95 | -123 | -91 | -126 | -60 | -27 | -13 |
| Net margin | 0.2% | -27.0% | -38.0% | -85.9% | -247.5% | -446.0% | -4613.5% | -2479.6% | -1706.6% | -1228.7% |
| Diluted EPS | $0.00 | -$0.37 | -$0.45 | -$0.70 | -$1.55 | -$2.23 | -$4.80 | — | — | — |
| Free cash flow | 28 | -38 | -49 | -103 | -97 | -81 | -105 | -58 | -25 | -16 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open XERS in Markets.
How Xeris Biopharma makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Recorlev | $56.8M | 61.7% |
| Gvoke | $22.5M | 24.5% |
| Keveyis | $11.7M | 12.7% |
| Royalty Contract & Other Revenue | $1.10M | 1.2% |
See also: XERS returns
No forecast, no recommendation. This page describes Xeris Biopharma Holdings Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.